Genetic profiling may play a greater role in identifying women at risk from breast cancer

October 24, 2001

A team of Cambridge University scientists has identified variants in six genes that may help to identify women at risk from breast cancer, ECCO 11 - the European Cancer Conference in Lisbon heard today. (Wednesday 24 October)

A strong family history, involving dominant genes, is already well established as a cause of breast cancer. Mutations in the so-called BRCA1 and 2 genes are estimated to account for about 15-20 per cent of familial breast cancer.

But the Cambridge research may lead to the development of further tests to identify women who are at risk from other genetic mutations. Professor Bruce Ponder, of the Cancer Research Campaign Department of Oncology at the university, said: "The number and type of genes that account for the remainder of familial breast cancer is not clear. It is, however, plausible, that at least some of this genetic predisposition is attributable to the effects of multiple, common, but individually weak genes".

Identifying such genes could help scientists to create "genotype profiles" to determine the risk of individual women at risk from the disease. These could be used in pre-symptomatic screening, diagnosis and treatment of the disease.

Professor Ponder believes that "genotype profiles" may ultimately prove to be more effective than "established clinical risk factors" in determining if an individual woman is at risk. These factors include age, reproductive factors including age of menarche (first period) and menopause, high-fat diet, alcohol consumption and high socio-economic status.

He explained: "These established risk factors are all very important, but they are not good discriminants of risk for the individual. It's been shown that if you take a series of ten thousand women and evaluate them according to these factors, you can predict fairly accurately how many of them will get breast cancer. But what you can't do is to tell which women will get it and which won't.

"We hope that the genetic profiles will be much more specific - and tell us which individuals are at high risk and which are not."

What is the next stage in the research? "This is a field which is at the very beginning. We now need our results to be replicated by two or three other groups."
Abstract no: 923.

Further information: Maria Maneiro
+351 21 892 1818 (till October 25)
+32 2 775 02 03 (from October 26)

ECCO-the European CanCer Organisation

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to